Trial Profile
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Jan 2021 Primary endpoint,Proportion of Participants With an Objective Response (Partial Response + Complete Response, has not been met as per Results published in the Investigational New Drugs
- 06 Jan 2021 Results published in the Investigational New Drugs
- 16 Dec 2020 Status changed from active, no longer recruiting to completed.